

Intelligent Software Solutions to Better Understand Biological Processes

Transinsight GmbH enters three year collaboration with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden


Dresden, December 19th, 2006 - Transinsight GmbH enters three year collaboration with the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden in the area of knowledge-based image analysis.

Founded in November 2005, Transinsight GmbH is a software company focused on the life sciences that provides products and solutions for knowledge-based technologies. Their flagship product, GoPubMed, a well established biomedical search engine, will be extended towards biomedical image search and knowledge-based image recognition. Especially particle tracking imagery produced by high throughput microscopy will be a focus in the upcoming years.

"The extraordinary scientific work performed at the MPI-CBG by Dr. Yannis Kalaidzidis in the area of particle tracking is an ideal start for collaboration. The close to practice testing of our developments at the MPI-CBG is an invaluable advantage for us" says Transinsight's CEO and co-founder, Dr. Michael R. Alvers.

Prof. Dr. Marino Zerial, Director at the MPI-CBG is happy to see the further development of intelligent software solutions urgently needed for today's high-throughput image-based experimental data. "For us it is essential to be able to extract more information from the new generation of image-based screens that are providing such an exciting opportunity to better understand biology as well as discover new and better drugs. Sophisticated software is an essential tool to allow us to analyse and make sense of the huge datasets as well as reveal hidden and unexpected interconnections" says Zerial.

Dr. Ivan Baines who fostered the collaboration and outlined the three year collaboration agreement between Transinsight and the MPI-CBG is enthusiastic about the upcoming development. "This kind of research-industry collaboration allows us to influence developments towards our needs" so he states, "with Transinsight we will develop a far more flexible and powerful application that will help solve problems beyond that for which it was originally developed. Such collaboration allows us to further our own research as well as help deliver an important research tool to the community".



About Transinsight

Founded in November 2005, Transinsight GmbH this year has successfully acquired its seed financing from the recently established German High-Tech Gründer Fonds. Coached by CatCap GmbH, the company also acquired an additional undisclosed sum from a private investor. Transinsight is focused on software solutions for the life sciences providing products for knowledge based technologies. Their flagship product, GoPubMed, a well established biomedical search engine, will be extended towards biomedical image search and knowledge based image recognition. Especially particle tracking images produced by high throughput microscopy will be a focus in the upcoming years. Transinsight is headquartered in one of the leading German biotech incubators, the BioInnovationCenter Dresden BIOZ, where science and business work under one roof.

For more information, please visit the company's website at www.transinsight.com, or www.biosaxony.com.

Contact:

Transinsight GmbH

Dr. Michael R. Alvers, CEO

Phone: ++49 (0) 351 463 400 59

E-mail: malvers@transinsight.com

About MPI-CBG

The Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) is one of 78 institutes of the Max Planck Society, an independent, non-profit organization in Germany. MPI-CBG was founded in 1998 and since February 2001, scientists from over 30 nations have been working under one roof. The Institute has a core staff of about 400 scientists, which form a network of 27 research groups covering different topics at the interface of cell biology and developmental biology including research investigating illnesses such as cancer or Alzheimer's disease. For example, at the MPI-CBG researchers study how the growth of cells is controlled and why this control process fails to function properly in cancer cells. Once science has an understanding of how cellular control systems work, currently incurable illnesses may be diagnosed earlier with a view to developing more effective treatments.

The MPI-CBG has forged partnerships with technology providers in many of its major areas of research since it believes that the greatest insight and new discoveries are made when innovations in new technologies allow problems in research to be addressed or investigated in new ways.

www.mpi-cbg.de

For further information, please contact:

MPI-CBG
Florian Frisch
Information Officer
Pfortenhauerstr. 108
01307 Dresden
Germany
Phone +49 351 210-2840
Fax +49 351 210 2020
eMail frisch@mpi-cbg.de